Loading…
Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching
Objectives To investigate and compare the effects of tadalafil and silodosin on lower urinary tract symptoms and voiding functions in men with non‐neurogenic detrusor underactivity. Methods A total of 126 treatment‐naive men with lower urinary tract symptoms diagnosed as non‐neurogenic detrusor unde...
Saved in:
| Published in: | International journal of urology 2021-04, Vol.28 (4), p.411-416 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73 |
| container_end_page | 416 |
| container_issue | 4 |
| container_start_page | 411 |
| container_title | International journal of urology |
| container_volume | 28 |
| creator | Matsukawa, Yoshihisa Majima, Tsuyoshi Funahashi, Yasuhito Fujita, Takashi Ishida, Shohei Kato, Masashi Gotoh, Momokazu |
| description | Objectives
To investigate and compare the effects of tadalafil and silodosin on lower urinary tract symptoms and voiding functions in men with non‐neurogenic detrusor underactivity.
Methods
A total of 126 treatment‐naive men with lower urinary tract symptoms diagnosed as non‐neurogenic detrusor underactivity received tadalafil (5 mg/day) or silodosin (8 mg/day) for 12 months. After propensity score matching, parameter changes from before administration to 12 months since treatment initiation were assessed based on subjective symptoms and urodynamic findings, including bladder contractility index and maximum urinary flow rate, and were compared between the tadalafil treatment group and the silodosin group. Detrusor underactivity was defined as bladder contractility index |
| doi_str_mv | 10.1111/iju.14481 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475090213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475090213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73</originalsourceid><addsrcrecordid>eNp1kUtuFDEQhi0EIkNgwQWQJTaw6MSPfrKLogBBkdiQteV2lxOPuu3Gj4lmxxE4CKfiJFSYwAIJb0qyv_qq5J-Ql5ydcDynbltOeF33_BHZYBWVYLV4TDZs4EPV804ckWcpbRnjUvD-KTmSUg6SN3JDflxYCyYnGizNetKztm6mO4ipJJrcHKaQnKfB011wk_M31BZvssMLvF70DHTV2YFHxZ3Lt9QH__Pbdw8lhhvwztAJciwpRFr8BFFj787l_Tt6Rk1YVh2xewc05TLtaUn3E9YYVvAJKZpMiIBjsrnFl-fkidVzghcP9Zhcv7_4cv6xuvr84fL87Koysut41bRggI1dq2U_Cg7AreQTG5iBwTIOPWdNq0Uz9TCO7TDUgzS1tbK3rLWd7eQxeXPw4iZfC6SsFpcMzLP2EEpSou4a1AkuEX39D7oNJXrcTglk8Lv7pkfq7YEyMaQUwao1ukXHveJM3UeoMEL1O0JkXz0Yy7jA9Jf8kxkCpwfgzs2w_79JXX66Pih_AWKXqwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509218858</pqid></control><display><type>article</type><title>Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Matsukawa, Yoshihisa ; Majima, Tsuyoshi ; Funahashi, Yasuhito ; Fujita, Takashi ; Ishida, Shohei ; Kato, Masashi ; Gotoh, Momokazu</creator><creatorcontrib>Matsukawa, Yoshihisa ; Majima, Tsuyoshi ; Funahashi, Yasuhito ; Fujita, Takashi ; Ishida, Shohei ; Kato, Masashi ; Gotoh, Momokazu</creatorcontrib><description>Objectives
To investigate and compare the effects of tadalafil and silodosin on lower urinary tract symptoms and voiding functions in men with non‐neurogenic detrusor underactivity.
Methods
A total of 126 treatment‐naive men with lower urinary tract symptoms diagnosed as non‐neurogenic detrusor underactivity received tadalafil (5 mg/day) or silodosin (8 mg/day) for 12 months. After propensity score matching, parameter changes from before administration to 12 months since treatment initiation were assessed based on subjective symptoms and urodynamic findings, including bladder contractility index and maximum urinary flow rate, and were compared between the tadalafil treatment group and the silodosin group. Detrusor underactivity was defined as bladder contractility index <100 and bladder outlet obstruction index <40.
Results
After propensity score matching, the final analysis included 48 patients each in the tadalafil and silodosin groups. No significant differences in prostate volume, subjective symptoms or urodynamic parameters were detected between the groups at baseline. Compared with baseline, significant improvements in subjective symptoms and storage and voiding functions were observed at month 12 in both groups. Maximum urinary flow rate significantly improved by 1.7 mL/s in the silodosin group and by 3.0 mL/s in the tadalafil group. In addition, the mean bladder contractility index increased from 80.0 to 86.1 in the silodosin group and from 77.9 to 97.6 in the tadalafil group. Improvements in maximum urinary flow rate and bladder contractility index were significantly superior in the tadalafil group.
Conclusions
Both tadalafil and silodosin significantly improve lower urinary tract symptoms and voiding function in patients with non‐neurogenic detrusor underactivity. Furthermore, tadalafil is more effective than silodosin in improving bladder contractility index and maximum urinary flow rate.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.14481</identifier><identifier>PMID: 33393153</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Bladder ; bladder contractility ; Contractility ; detrusor underactivity ; lower urinary tract symptoms ; Prostate ; silodosin ; tadalafil ; Urinary tract ; Urogenital system</subject><ispartof>International journal of urology, 2021-04, Vol.28 (4), p.411-416</ispartof><rights>2021 The Japanese Urological Association</rights><rights>2021 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73</citedby><cites>FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73</cites><orcidid>0000-0001-7823-2600</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33393153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsukawa, Yoshihisa</creatorcontrib><creatorcontrib>Majima, Tsuyoshi</creatorcontrib><creatorcontrib>Funahashi, Yasuhito</creatorcontrib><creatorcontrib>Fujita, Takashi</creatorcontrib><creatorcontrib>Ishida, Shohei</creatorcontrib><creatorcontrib>Kato, Masashi</creatorcontrib><creatorcontrib>Gotoh, Momokazu</creatorcontrib><title>Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objectives
To investigate and compare the effects of tadalafil and silodosin on lower urinary tract symptoms and voiding functions in men with non‐neurogenic detrusor underactivity.
Methods
A total of 126 treatment‐naive men with lower urinary tract symptoms diagnosed as non‐neurogenic detrusor underactivity received tadalafil (5 mg/day) or silodosin (8 mg/day) for 12 months. After propensity score matching, parameter changes from before administration to 12 months since treatment initiation were assessed based on subjective symptoms and urodynamic findings, including bladder contractility index and maximum urinary flow rate, and were compared between the tadalafil treatment group and the silodosin group. Detrusor underactivity was defined as bladder contractility index <100 and bladder outlet obstruction index <40.
Results
After propensity score matching, the final analysis included 48 patients each in the tadalafil and silodosin groups. No significant differences in prostate volume, subjective symptoms or urodynamic parameters were detected between the groups at baseline. Compared with baseline, significant improvements in subjective symptoms and storage and voiding functions were observed at month 12 in both groups. Maximum urinary flow rate significantly improved by 1.7 mL/s in the silodosin group and by 3.0 mL/s in the tadalafil group. In addition, the mean bladder contractility index increased from 80.0 to 86.1 in the silodosin group and from 77.9 to 97.6 in the tadalafil group. Improvements in maximum urinary flow rate and bladder contractility index were significantly superior in the tadalafil group.
Conclusions
Both tadalafil and silodosin significantly improve lower urinary tract symptoms and voiding function in patients with non‐neurogenic detrusor underactivity. Furthermore, tadalafil is more effective than silodosin in improving bladder contractility index and maximum urinary flow rate.</description><subject>Bladder</subject><subject>bladder contractility</subject><subject>Contractility</subject><subject>detrusor underactivity</subject><subject>lower urinary tract symptoms</subject><subject>Prostate</subject><subject>silodosin</subject><subject>tadalafil</subject><subject>Urinary tract</subject><subject>Urogenital system</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kUtuFDEQhi0EIkNgwQWQJTaw6MSPfrKLogBBkdiQteV2lxOPuu3Gj4lmxxE4CKfiJFSYwAIJb0qyv_qq5J-Ql5ydcDynbltOeF33_BHZYBWVYLV4TDZs4EPV804ckWcpbRnjUvD-KTmSUg6SN3JDflxYCyYnGizNetKztm6mO4ipJJrcHKaQnKfB011wk_M31BZvssMLvF70DHTV2YFHxZ3Lt9QH__Pbdw8lhhvwztAJciwpRFr8BFFj787l_Tt6Rk1YVh2xewc05TLtaUn3E9YYVvAJKZpMiIBjsrnFl-fkidVzghcP9Zhcv7_4cv6xuvr84fL87Koysut41bRggI1dq2U_Cg7AreQTG5iBwTIOPWdNq0Uz9TCO7TDUgzS1tbK3rLWd7eQxeXPw4iZfC6SsFpcMzLP2EEpSou4a1AkuEX39D7oNJXrcTglk8Lv7pkfq7YEyMaQUwao1ukXHveJM3UeoMEL1O0JkXz0Yy7jA9Jf8kxkCpwfgzs2w_79JXX66Pih_AWKXqwQ</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Matsukawa, Yoshihisa</creator><creator>Majima, Tsuyoshi</creator><creator>Funahashi, Yasuhito</creator><creator>Fujita, Takashi</creator><creator>Ishida, Shohei</creator><creator>Kato, Masashi</creator><creator>Gotoh, Momokazu</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7823-2600</orcidid></search><sort><creationdate>202104</creationdate><title>Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching</title><author>Matsukawa, Yoshihisa ; Majima, Tsuyoshi ; Funahashi, Yasuhito ; Fujita, Takashi ; Ishida, Shohei ; Kato, Masashi ; Gotoh, Momokazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bladder</topic><topic>bladder contractility</topic><topic>Contractility</topic><topic>detrusor underactivity</topic><topic>lower urinary tract symptoms</topic><topic>Prostate</topic><topic>silodosin</topic><topic>tadalafil</topic><topic>Urinary tract</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsukawa, Yoshihisa</creatorcontrib><creatorcontrib>Majima, Tsuyoshi</creatorcontrib><creatorcontrib>Funahashi, Yasuhito</creatorcontrib><creatorcontrib>Fujita, Takashi</creatorcontrib><creatorcontrib>Ishida, Shohei</creatorcontrib><creatorcontrib>Kato, Masashi</creatorcontrib><creatorcontrib>Gotoh, Momokazu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsukawa, Yoshihisa</au><au>Majima, Tsuyoshi</au><au>Funahashi, Yasuhito</au><au>Fujita, Takashi</au><au>Ishida, Shohei</au><au>Kato, Masashi</au><au>Gotoh, Momokazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>28</volume><issue>4</issue><spage>411</spage><epage>416</epage><pages>411-416</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objectives
To investigate and compare the effects of tadalafil and silodosin on lower urinary tract symptoms and voiding functions in men with non‐neurogenic detrusor underactivity.
Methods
A total of 126 treatment‐naive men with lower urinary tract symptoms diagnosed as non‐neurogenic detrusor underactivity received tadalafil (5 mg/day) or silodosin (8 mg/day) for 12 months. After propensity score matching, parameter changes from before administration to 12 months since treatment initiation were assessed based on subjective symptoms and urodynamic findings, including bladder contractility index and maximum urinary flow rate, and were compared between the tadalafil treatment group and the silodosin group. Detrusor underactivity was defined as bladder contractility index <100 and bladder outlet obstruction index <40.
Results
After propensity score matching, the final analysis included 48 patients each in the tadalafil and silodosin groups. No significant differences in prostate volume, subjective symptoms or urodynamic parameters were detected between the groups at baseline. Compared with baseline, significant improvements in subjective symptoms and storage and voiding functions were observed at month 12 in both groups. Maximum urinary flow rate significantly improved by 1.7 mL/s in the silodosin group and by 3.0 mL/s in the tadalafil group. In addition, the mean bladder contractility index increased from 80.0 to 86.1 in the silodosin group and from 77.9 to 97.6 in the tadalafil group. Improvements in maximum urinary flow rate and bladder contractility index were significantly superior in the tadalafil group.
Conclusions
Both tadalafil and silodosin significantly improve lower urinary tract symptoms and voiding function in patients with non‐neurogenic detrusor underactivity. Furthermore, tadalafil is more effective than silodosin in improving bladder contractility index and maximum urinary flow rate.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33393153</pmid><doi>10.1111/iju.14481</doi><tpages>0</tpages><orcidid>https://orcid.org/0000-0001-7823-2600</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2021-04, Vol.28 (4), p.411-416 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2475090213 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Bladder bladder contractility Contractility detrusor underactivity lower urinary tract symptoms Prostate silodosin tadalafil Urinary tract Urogenital system |
| title | Effects of tadalafil versus silodosin on voiding function in male patients with non‐neurogenic detrusor underactivity: A comparative study using propensity score matching |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A22%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20tadalafil%20versus%20silodosin%20on%20voiding%20function%20in%20male%20patients%20with%20non%E2%80%90neurogenic%20detrusor%20underactivity:%20A%20comparative%20study%20using%20propensity%20score%20matching&rft.jtitle=International%20journal%20of%20urology&rft.au=Matsukawa,%20Yoshihisa&rft.date=2021-04&rft.volume=28&rft.issue=4&rft.spage=411&rft.epage=416&rft.pages=411-416&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.14481&rft_dat=%3Cproquest_cross%3E2475090213%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3771-56ece0b76a38b21ee1f31d090ce9f01e81056a25d8ebb699493c4ff38f06f7f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2509218858&rft_id=info:pmid/33393153&rfr_iscdi=true |